Tumor cells can also hijack caspase-9 signaling to suppress radiation-induced immunity; deletion of caspase-9 or pharmacological pan-caspase inhibition with Emricasan can sensitize cancer cells to radiation therapy by rescuing type I interferon production in irradiated cells (Han et al., 2020a). Here, CASP9 is linked to neoplasm.